Surgical management of mammary tumour in canines


Published on

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Surgical management of mammary tumour in canines

  1. 1. “ SURGICAL MANAGEMENT OF MAMMARY TUMOUR IN CANINE” Presented By – Dr. Manzoor Ahmad bhat m. v. sc. Scholar Department of Veterinary Surgery and Radiology
  2. 2. MAMMARY TUMOUR (MT) <ul><li>Neoplasia which involve mammary gland </li></ul><ul><li>Most common in bitches, rare in male(1%) </li></ul><ul><li>MT consist of 50% of all tumours in bitch </li></ul><ul><li>Malignant or benign </li></ul><ul><li>30% to 50% are malignant </li></ul><ul><li>malignant tumours spread through lymphatics and blood vessels primarily to regional lymph nodes and lungs </li></ul><ul><li>Other metastatic sites include adrenal glands, kidneys, heart and bones </li></ul>20/11/2010
  3. 3. PATHOLOGICAL ASPECT <ul><li>Benign tumours are usually fibroadenoma, adenomas or mesenchymal tumours </li></ul><ul><li>Most malignant tumours are carcinomas and these tend to spread after surgery </li></ul>20/11/2010
  4. 4. ETIOLOGY <ul><li>Unknown </li></ul><ul><li>Hormone dependent </li></ul><ul><li>Estrogen and progesterone seems to have a role </li></ul><ul><li>Estrogen and progesterone receptors are found in 50% malignant and 70% of benign canine MTs </li></ul>20/11/2010
  5. 5. OHE AND MAMMARY TUMOUR <ul><li>MT are prevented if OHE is done before 1 year of age </li></ul><ul><li>Risk of developing MT is only 0.05% in bitches spayed before 1 st estrous </li></ul><ul><li>Risk increases to 8% and 26% after 1st and 2 nd estrous respectively </li></ul><ul><li>No effect of OHE on MT after 2.5years </li></ul>20/11/2010
  6. 6. CASE HISTORY <ul><ul><ul><li>Case no. </li></ul></ul></ul><ul><ul><ul><li>Date: 7/10/10 </li></ul></ul></ul><ul><ul><ul><li>Spp: canine </li></ul></ul></ul><ul><ul><ul><li>Breed: labrador </li></ul></ul></ul><ul><ul><ul><li>Age: 10 years </li></ul></ul></ul><ul><ul><ul><li>Sex: Female </li></ul></ul></ul><ul><ul><ul><li>Colour: fawn </li></ul></ul></ul><ul><ul><ul><li>Weight: 27 kg </li></ul></ul></ul>20/11/2010
  7. 7. HISTORY <ul><li>Hard lump present on abdomen for last 2 months </li></ul><ul><li>Fast growing </li></ul><ul><li>Non pregnant and non lactating for last 2 years </li></ul><ul><li>Engorgement of teats before 6 month </li></ul>20/11/2010
  8. 8. PHYSICAL FINDINGS <ul><li>Tumour like growth of about 12cm diameter involving 2 nd right teat </li></ul><ul><li>Ulcerated growth was firm but easily movable below the skin </li></ul><ul><li>All physiological parameters were found to be normal </li></ul><ul><li>Right axillary lymph nodes were palpable (slight swollen) </li></ul>20/11/2010
  9. 9. DIAGNOSIS 20/11/2010 <ul><li>Based on history and visual observation </li></ul>Mammary Tumour
  10. 10. TREATMENT <ul><li>Medicinal management </li></ul><ul><li>Antiestrogens (tamoxifen @0.4 to 0.8mg/kg/d PO), antiprogestins or antiprolactins are advocated by some. </li></ul><ul><li>Chemotherapy but no particular protocol. Adriamycin and cyclophosphamide combinations are used </li></ul><ul><li>Radiation therapy </li></ul><ul><li>Immunotherapy </li></ul><ul><li>Surgical excision is the treatment of choice </li></ul><ul><li>So it was adopted with out any delay </li></ul>20/11/2010
  11. 11. PREOPERATIVE MANAGEMENT <ul><li>0.5mg/kg of Pheneramine maleate was given i/m </li></ul><ul><li>1ml of dexamethasone s/c </li></ul><ul><li>Carbazochrome salicylate 1ml i/m </li></ul>20/11/2010
  12. 12. PRE ANESTHETICS <ul><li>Triflupromazine HCL @ 1mg/kg body weight i/v </li></ul><ul><li>Atropine sulphate @0.04mg/kg body weight s/c </li></ul>20/11/2010
  13. 13. PREPARATION OF SURGICAL SITE <ul><li>Savlon was applied on the intended area and shaving was done liberally to prepare the site </li></ul>20/11/2010
  14. 14. ANESTHESIA <ul><li>Thiopentone Na @ 20mg/kg body weight i/v </li></ul><ul><li>5% solution was prepared and 1/3 rd was sufficient for induction </li></ul><ul><li>2/3 rd was used for maintenance </li></ul><ul><li>Total dose of 300mg was sufficient for the whole surgical procedure to complete successfully </li></ul>20/11/2010
  15. 15. SURGICAL PROCEDURE 20/11/2010
  16. 16. POST-OPERATIVE THERAPY <ul><li>Antibiotics – ceftriaxone 500 mg i/m for 5 days </li></ul><ul><li>NSAID- meloxicam @ 0.5 mg/kg for 5 days </li></ul><ul><li>Antihistaminic- pheneramine maleate </li></ul><ul><li>@ 0.5mg/kg for 4 more days </li></ul><ul><li>RL 200ml i/v for 2days </li></ul><ul><li>Daily dressing of surgical wound for 5 days. </li></ul>20/11/2010
  17. 17. 20/11/2010